Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial.

Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Abstract Text:

Andreas Meunier, Lisander,Lars Good,

BACKGROUND: Pain management after surgery has been used as a sales argument for the use of COX-2 inhibitors, but their potential positive and negative effects have not been fully investigated. We thus conducted a controlled evaluation of the effect of celecoxib on perioperative blood loss, pain relief and consumption of analgesics, range of motion, and subjective outcome in conjunction with total knee replacement (TKR). METHOD: 50 patients were randomized to either placebo or celecoxib (200 mg) preoperatively and then twice daily. Total blood loss was calculated by the Hb balance method, taking the patient's pre- and postoperative hemoglobin and blood volume into account. Pain scores (VAS), range of motion, and subjective outcome (KOOS) were monitored postoperatively and during the first year after surgery. RESULTS: No differences in total, hidden, or drainage blood loss were found between the groups. There were 30% lower pain scores during the first 4 weeks after surgery and lower morphine consumption after surgery in the celecoxib group, while no effect was seen on pain, range of motion, and subjective outcome at the 1 year follow-up. INTERPRETATION: Celecoxib does not increase perioperative blood loss but reduces pain during the postoperative period after TKR. It is not necessary to discontinue celecoxib before surgery. The postoperative use of celecoxib did not increase range of motion or subjective outcome 1 year after TKR.

Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Publishing Authors By Initials

A Meunier,B Lisander,L Good,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: Acta orthopaedica

VOLUME: 78

Page Numbers: 661-7

Journal Abbreviation:

ISSN: 1745-3674

DAY: 28

MONTH: Oct

YEAR: 2007

Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101231512

Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: adverse effects

Chemical & Substance for Abstract: Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial. Information

Substance Name: celecoxib

Registry Number: 169590-42-5

Grant and Affiliation Information for Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial.

AFFILIATION: Division of Orthopaedics and Sports Medicine, University of Linköping, Sweden. andreas.meunier@lio.se

Country: Sweden

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Orthop

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial Related Publications

• A case for whole-parasite malaria vaccines.
• A rapid method to measure beta-amyloid induced neurotoxicity in vitro.
• A small epidemic with meningeal symptoms simulating leptospiral infection.
• Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.
• Antigen-antibody mechanisms in neurotropic virus diseases.
• Attenuation of beta-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers.
• Attenuation of beta-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: role of sialic acid attachment.
• Culture and stigma: adding moral experience to stigma theory.
• Determinants of complementary and alternative medicine use by patients with bipolar disorder.
• Diagnosis and treatment of low backache.
• Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: a randomized placebo-controlled trial.
• Energy balance pathways converging on the Nhlh2 transcription factor.
• Expression of the hypothalamic transcription factor Nhlh2 is dependent on energy availability.
• Group clinic starts a new chapter in the history of rural medical care.
• Immunodeficiency, radiosensitivity, and the XCIND syndrome.
• Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
• Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
• Introduction: Robert A. Good Immunology Conference 2007.
• Lack of identity of hyaluronidase inhibitor and certain mucoproteins in blood serum.
• Nongenomic actions of aldosterone on the renal tubule.
• Novel DOCK clique driven 3D similarity database search tools for molecule shape matching and beyond: adding flexibility to the search for ligand kin.
• Reliability and Validity of the Sensewear Pro Armband During Continuous Functional Resistance Exercise: 1301: Board #64 May 30 9:30 AM - 11:00 AM.
• Response 2.
• Robert A Good and Ludwig van Beethoven: immortal beloveds: summary of the Robert A Good Immunology Society: Perspective in Immunology 2006 June 9-12 2006 St. Pete Beach, Florida.
• Robert A. Good, the March of Dimes, and immunodeficiency: an historical perspective.
• Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Abeta fibril formation pathway.
• Targeted deletion of the GluR-1 AMPA receptor in mice dissociates general and outcome-specific influences of appetitive rewards on learning.
• Technology and retinopathy of prematurity diagnosis: the new frontier.
• The importance of exploratory thoracotomy in the diagnosis of certain pulmonary lesions.
• The spectrum of vision impairment caused by pediatric neurological injury.